Pharnext (FR:ALPHA) has released an update.
Pharnext, a biopharmaceutical company focused on neurodegenerative diseases, is facing challenges in communicating the results of a key clinical trial due to a partner’s refusal, impacting potential deals for their drug candidate PXT3003 and creditor discussions. The company’s financial stability is further threatened by a lack of additional support from their strategic partner Néovacs, and Pharnext is exploring legal options to address its current situation while cautioning investors about possible share value dilution from financing operations.
For further insights into FR:ALPHA stock, check out TipRanks’ Stock Analysis page.
